Startup Magenta Therapeutics licences technologies from Harvard, MGH, and Boston Children's that could transform treatment of blood diseases and immune disorders
Harvard University has completed a license agreement with Magenta Therapeutics, a new startup company launched in Cambridge, for a portfolio of technologies with the potential to transform blood stem cell transplants from a “treatment of last resort” into a safer, more efficient therapy for patients with blood diseases...
Read more about HSCI research inspires startup
HSCI codirector David Scadden has been named a Fellow of the American Association for the Advancement of Science (AAAS). 
Using large-scale zebrafish drug-screening models,...